24.12.2012 Views

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

LBA1000 Oral Abstract Session, Tue, 9:45 AM-12:45 PM<br />

NSABP B-38: Definitive analysis <strong>of</strong> a randomized adjuvant trial comparing<br />

dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with<br />

DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide<br />

(TAC) in women with operable, node-positive breast cancer. Presenting<br />

Author: Sandra M. Swain, National Surgical Adjuvant Breast and Bowel<br />

Project and Washington Cancer Institute, MedStar Washington Hospital<br />

Center, Washington, DC<br />

The full, final text <strong>of</strong> this abstract will be available at<br />

abstract.asco.org at 12:01 AM (EDT) on Monday, June 4,<br />

2012, and in the <strong>Annual</strong> <strong>Meeting</strong> <strong>Proceedings</strong> online<br />

supplement to the June 20, 2012, issue <strong>of</strong> Journal <strong>of</strong><br />

<strong>Clinical</strong> Oncology. Onsite at the <strong>Meeting</strong>, this abstract will<br />

be printed in the Monday edition <strong>of</strong> ASCO Daily News.<br />

CRA1002 Oral Abstract Session, Tue, 9:45 AM-12:45 PM<br />

CALGB 40502/NCCTG N063H: Randomized phase III trial <strong>of</strong> weekly<br />

paclitaxel (P) compared to weekly nanoparticle albumin bound nabpaclitaxel<br />

(NP) or ixabepilone (Ix) with or without bevacizumab (B) as<br />

first-line therapy for locally recurrent or metastatic breast cancer (MBC).<br />

Presenting Author: Hope S. Rugo, University <strong>of</strong> California, San Francisco<br />

Helen Diller Family Comprehensive Cancer Center, San Francisco, CA<br />

The full, final text <strong>of</strong> this abstract will be available at<br />

abstract.asco.org at 12:01 AM (EDT) on Monday, June 4,<br />

2012, and in the <strong>Annual</strong> <strong>Meeting</strong> <strong>Proceedings</strong> online<br />

supplement to the June 20, 2012, issue <strong>of</strong> Journal <strong>of</strong><br />

<strong>Clinical</strong> Oncology. Onsite at the <strong>Meeting</strong>, this abstract will<br />

be printed in the Monday edition <strong>of</strong> ASCO Daily News.<br />

Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy<br />

49s<br />

1001 Oral Abstract Session, Tue, 9:45 AM-12:45 PM<br />

Randomized phase III study <strong>of</strong> adjuvant chemotherapy for high-risk,<br />

node-negative breast cancer (BC) comparing FAC with FAC followed by<br />

weekly paclitaxel: First efficacy analysis <strong>of</strong> the GEICAM/2003-02 trial.<br />

Presenting Author: Miguel Martin, Hospital General Universitario Gregorio<br />

Marañón, Madrid, Spain<br />

Background: Adjuvant weekly paclitaxel (wP) sequential to anthracyclines<br />

improves the outcome <strong>of</strong> operable node-positive BC patients (pts) [Sparano<br />

NEJM 2008, Martin BCRT 2009]; however, most BC pts are currently<br />

node-negative at diagnosis. The role <strong>of</strong> wP in these pts is not well<br />

established yet. Methods: Pts aged 18-70, with T1-T3/N0 operable BC and<br />

at least one high-risk St Gallen 1998 criteria (size �2 cm, hormonereceptor<br />

[HR] negative, grade 2/3, age �35 years,) were eligible. HER2�<br />

pts were allowed, after 792 entered the trial, the study was amended to<br />

exclude them. Pts were stratified by site, menopausal status, nodal status<br />

diagnostic method (sentinel-node biopsy versus lymphadenectomy) and<br />

HR status and randomized to receive FAC x6 (500/50/500 mg/m2 every<br />

3w) or FAC x4¡wP x8 (paclitaxel 100 mg/m2 weekly). The primary<br />

endpoint was DFS. The trial was designed to detect an absolute 5-y DFS<br />

increase <strong>of</strong> 5% (80% FAC, 85% FAC¡wP); a sample size <strong>of</strong> 1812<br />

evaluable patients (906 per arm) was required to detect this difference<br />

(��0.05, �� 80%). Assuming a drop-out rate <strong>of</strong> 6%, 1929 pts were<br />

required. The first analysis <strong>of</strong> DFS was planned when a median follow-up <strong>of</strong><br />

5 years was reached. Results: Between September 2003 and October<br />

2008, 1925 pts (FAC 974, FAC¡wP 951) were randomized. Patient<br />

characteristics were well balanced between arms, median age was 50, 73%<br />

<strong>of</strong> pts were HR positive and 9% HER2 positive. 97% <strong>of</strong> pts with FAC and<br />

85% <strong>of</strong> pts with FAC¡wP completed all treatment as planned. The median<br />

dose intensity was 98% with FACx6, 99% with FACx4 and 98% with wP.<br />

The most frequent grade 3-4 toxicities (�3% in either arm) with FAC vs<br />

FAC¡wP were neutropenia (25% vs 22%) with 4% vs 3% <strong>of</strong> febrile<br />

neutropenia, fatigue (3% vs 8%), sensory neuropathy (0 vs 5%), and<br />

vomiting (4% in each arm). After a median follow-up <strong>of</strong> 5.3 years, the<br />

proportion <strong>of</strong> patients disease free is 93% and 90% with FAC¡wP and FAC<br />

(HR for relapse 0.732, 95% CI: 0.542 to 0.990; log-rank p-value�0.0423).<br />

Conclusions: For pts with high-risk node-negative BC, adjuvant FAC¡wP<br />

was associated with a small but significant improvement in DFS compared<br />

with FAC, with manageable toxicity.<br />

1003 Oral Abstract Session, Tue, 9:45 AM-12:45 PM<br />

A phase III, multicenter, randomized trial <strong>of</strong> maintenance versus observation<br />

after achieving clinical response in patients with metastatic breast<br />

cancer who received six cycles <strong>of</strong> gemcitabine plus paclitaxel as first-line<br />

chemotherapy (KCSG-BR 0702, NCT00561119). Presenting Author:<br />

Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea<br />

Background: Chemotherapy provides a survival benefit in patients with<br />

metastatic breast cancer (MBC), but the optimal duration <strong>of</strong> chemotherapy<br />

remains controversial. Primary purpose <strong>of</strong> the study was to evaluate<br />

whether the maintenance chemotherapy with gemcitabine/paclitaxel (GP),<br />

which is one <strong>of</strong> the two regimens which showed a survival gain from a<br />

randomized trial, is superior to observation in terms <strong>of</strong> progression free<br />

survival (PFS) in responding patients with MBC after 6 cycles <strong>of</strong> GP as<br />

first-line treatment. Methods: This study is a prospective, randomized,<br />

multi-center, phase III study. Patients who achieved response (CR�PR�SD)<br />

following 6 cycles <strong>of</strong> GP chemotherapy (gemcitabine 1250 mg/m2 on day 1<br />

and 8 plus paclitaxel 175 mg/m2 on day 1 every 3 weeks) randomized to<br />

maintenance till progression or observation arm. The trial was conducted by<br />

the Korean Cancer Study Group (KCSG). Results: Among total 324 patients<br />

enrolled between 2007 and 2010 from 10 centers, 231 responding<br />

patients to were randomly assigned to maintenance chemotherapy (n�116)<br />

or observation (n�115). Median age was 49 (range 28-76). The numbers<br />

<strong>of</strong> hormone receptor (HR)�ve and HR-ve patients were 172 (74.5%) and<br />

59 (25.5%), respectively. The median No. <strong>of</strong> chemotherapy cycles in<br />

maintenance group was 12 (range 6-32). During median 33 months <strong>of</strong><br />

follow-up, median PFS was superior in maintenance than in observation<br />

(12.0 vs. 8.3 months, p�0.030). Patients � age 50 years (hazard ratio<br />

0.50, p�0.001) and HR-ve patients (hazard ratio 0.52, p�0.019)<br />

received more benefit from maintenance chemotherapy in terms <strong>of</strong> PFS.<br />

Median OS was superior in maintenance than in observation (36.8 vs 28.0<br />

months, p�0.047). Neurotoxicity (� grade 2) was more common in<br />

maintenance than in observation without statistical significance (41.7% vs<br />

33.3%, p�0.210). Serial assessment <strong>of</strong> Quality <strong>of</strong> Life (QoL) did not show<br />

any significant difference between two groups. Conclusions: Maintenance<br />

GP chemotherapy for responding patients with MBC showed clinical benefit<br />

in terms <strong>of</strong> PFS and OS without impairment <strong>of</strong> QoL.<br />

Visit abstract.asco.org and search by abstract for the full list <strong>of</strong> abstract authors and their disclosure information.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!